FilingReader Intelligence
Dr. Reddy's reports 11% revenue growth in Q1
July 23, 2025 at 11:19 AM UTC•By FilingReader AI
Dr. Reddy's Laboratories reported Q1 FY26 revenues of ₹8,545 crore, up 11% year-over-year. EBITDA reached ₹2,278 crore with a 26.7% margin.
Global Generics revenue rose 10% to ₹7,562 crore, with North America contributing ₹3,412 crore and India ₹1,471 crore. The company launched two innovative assets in India and completed USFDA inspections at three sites.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:DRREDDY•Bombay Stock Exchange
News Alerts
Get instant email alerts when Dr. Reddy's Laboratories publishes news
Free account required • Unsubscribe anytime